News Alexion lambasts NICE over rare disease ruling Watchdog accused of ignoring stakeholder consensus and call for negotiations
News Alexion drug fails in kidney transplant trial Soliris fails when used to treat post-transplant complications.
News Alexion's new CFO promises to put cash to good use After announcing the shock departure of Alexion's chief executive and chief financial officer yesterday, the company's chairman Leonard Bell quickly named David Brennan, ex-AstraZeneca chie
Articles Alexion: aiming to break new ground in ultra-rare therapies Martin Mackay, head of R&D at Alexion, talks to pharmaphorum about the company's research pipeline for severe and ultra-rare diseases.
News Kanuma approval adds to Alexion rare disease roster Alexion has gained FDA approval for Kanuma, its treatment for the rare disease lysosomal acid lipase (LAL) deficiency.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
